Aldeyra net loss narrows 44.2% to $5.45 million in Q2 2026 - ALDX News | RalliesAldeyra net loss narrows 44.2% to $5.45 million in Q2 2026
A
ALDX• Q2 2026 results
- Aldeyra Therapeutics posted a GAAP net loss of USD 5.45 million for Q2 2026, narrowing 44.2% from a loss of USD 9.77 million.
- Operating loss improved 42.5% to USD 5.85 million, as research and development expense fell 59% to USD 3.48 million.
- General and administrative expense rose 42.2% to USD 2.37 million, while interest income dropped 54.1% to USD 400,257.
- Cash and cash equivalents totaled USD 45.1 million at June 30, 2026; the company said it expects funding into the second half of 2028.
- AbbVie has not exercised its reproxalap option as of Aug. 6, 2026; Aldeyra repaid its USD 15 million Hercules loan on April 1, 2026.
